Myriad Genetics And Illumina Announced Two Key Milestones In Strategic Partnership To Support Biopharma Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics and Illumina have achieved two key milestones in their strategic partnership aimed at advancing genomic profiling and homologous recombination deficiency (HRD) testing. The first milestone qualifies Myriad to conduct prospective clinical trial testing with an investigational use only test based off of Illumina's in-development IVD solution. The second milestone involves Myriad's initiation of its first reproducibility test project to support future regulatory filings.
September 19, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Illumina's in-development IVD solution is being used by Myriad Genetics in their strategic partnership, marking key milestones in the advancement of genomic profiling and HRD testing.
The use of Illumina's in-development IVD solution by Myriad Genetics in their strategic partnership indicates progress and potential future success for the product. This could potentially lead to increased investor confidence and a rise in Illumina's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Myriad Genetics has achieved two key milestones in its partnership with Illumina, positioning it to partner with leading pharmaceutical companies and academic institutions for the development of companion diagnostics.
The achievement of these milestones indicates progress in Myriad's strategic partnership with Illumina, which could potentially lead to new opportunities and collaborations for the company. This is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100